CD19 and diffuse large B-cell lymphoma: Evidence of such an effect was demonstrated in an anti-CD19 CAR-T cell trial in which the debulking of patients with intensive chemotherapy prior to lymphodepletion significantly improved overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma [104].